TY - JOUR
T1 - Antithrombotic treatment patterns and stroke prevention in patients with atrial fibrillation in Turkey
T2 - Inferences from GARFIELD-AF registry
AU - Sayın, Begüm Yetiş
AU - Okutucu, Sercan
AU - Yılmaz, Mehmet Birhan
AU - Özdemir, Kurtuluş
AU - Aydınlar, Ali
AU - Şahin, Durmuş Yıldıray
AU - Altun, Armağan
AU - Açıkel, Sadık
AU - Okuyan, Ertuğrul
AU - Sucu, Murat
AU - Öngen, Zeki
AU - Ersanlı, Murat Kazım
AU - Yılmaz, Özcan
AU - Demir, Mesut
AU - Pekdemir, Hasan
AU - Topsakal, Ramazan
AU - Şahiner, Mehmet Levent
AU - Aras, Dursun
AU - Oto, Ali
N1 - Publisher Copyright:
© Copyright 2019 by Turkish Society of Cardiology.
PY - 2019/5
Y1 - 2019/5
N2 - Objective: The corner stone of atrial fibrillation therapy includes the prevention of stroke with less adverse effects. The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) study provided data to compare treatment strategies in Turkey with other populations and every-day practice of stroke prevention management with complications. Methods: GARFIELD-AF is a large-scale registry that enrolled 52,014 patients in five sequential cohorts at >1.000 centers in 35 countries. This study was initiated to track the evolution of global anticoagulation practice, and to study the impact of NOAC therapy in AF. A total of 756 patients from 17 enrolling sites in Turkey were in cohort 4 and 5. Treatment strategies at diagnosis initiated by CHA2DS2-VASc score, baseline characteristics of patients, treatment according to stroke and bleeding risk profiles, and INR values were analyzed in cohorts. Additionally, event rates during the first year follow up were evaluated. Results: AF patients in Turkey were mostly seen in young women. Stroke risk according to the CHADS2 score and CHA2DS2-VASc score compared with world data. The mean of risk score values, including HAS-BLED score were lower in Turkey than in the world data. The percentage of patients receiving FXa inhibitor with or without an antiplatelet usage was more than the other drug groups. All-cause mortality was higher in Turkey. Different form world data when HAS-BLED score was above 3, the therapy was mostly changed to antiplatelet drugs in Turkey. Conclusion: In addition to deficiencies in available treatment options, patient care and clinical outcomes of patients with AF, the data of GARFIELD- AF provide data from Turkey about therapeutic strategies and best practices. (Anatol J Cardiol 2019; 21: 272-80).
AB - Objective: The corner stone of atrial fibrillation therapy includes the prevention of stroke with less adverse effects. The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) study provided data to compare treatment strategies in Turkey with other populations and every-day practice of stroke prevention management with complications. Methods: GARFIELD-AF is a large-scale registry that enrolled 52,014 patients in five sequential cohorts at >1.000 centers in 35 countries. This study was initiated to track the evolution of global anticoagulation practice, and to study the impact of NOAC therapy in AF. A total of 756 patients from 17 enrolling sites in Turkey were in cohort 4 and 5. Treatment strategies at diagnosis initiated by CHA2DS2-VASc score, baseline characteristics of patients, treatment according to stroke and bleeding risk profiles, and INR values were analyzed in cohorts. Additionally, event rates during the first year follow up were evaluated. Results: AF patients in Turkey were mostly seen in young women. Stroke risk according to the CHADS2 score and CHA2DS2-VASc score compared with world data. The mean of risk score values, including HAS-BLED score were lower in Turkey than in the world data. The percentage of patients receiving FXa inhibitor with or without an antiplatelet usage was more than the other drug groups. All-cause mortality was higher in Turkey. Different form world data when HAS-BLED score was above 3, the therapy was mostly changed to antiplatelet drugs in Turkey. Conclusion: In addition to deficiencies in available treatment options, patient care and clinical outcomes of patients with AF, the data of GARFIELD- AF provide data from Turkey about therapeutic strategies and best practices. (Anatol J Cardiol 2019; 21: 272-80).
KW - Anticoagulation
KW - Atrial fibrillation
KW - Stroke
UR - https://www.scopus.com/pages/publications/85065650573
U2 - 10.14744/AnatolJCardiol.2019.78178
DO - 10.14744/AnatolJCardiol.2019.78178
M3 - Article
C2 - 31062761
AN - SCOPUS:85065650573
SN - 2149-2263
VL - 21
SP - 272
EP - 280
JO - Anatolian Journal of Cardiology
JF - Anatolian Journal of Cardiology
IS - 5
ER -